TLK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Su-9516 (SCHEMBL1170686)	1.00	15/20
Su-9516 (SCHEMBL1170687)	1.00	15/20
SCHEMBL1395124	1.00	14/20
SCHEMBL1395126	1.00	14/20
SCHEMBL394613	0.81	9/20
SCHEMBL394614	0.81	9/20
SCHEMBL20762	0.70	9/20
SCHEMBL20763	0.70	9/20
SCHEMBL25111	0.69	9/20
SCHEMBL1389040	0.55	9/20
SCHEMBL1304322	0.48	9/20
SCHEMBL20944	1.00	8/20
SCHEMBL20945	1.00	8/20
SCHEMBL1388800	0.57	8/20
SCHEMBL395278	0.52	8/20
SCHEMBL395279	0.52	8/20
SCHEMBL398830	0.89	7/20
SCHEMBL398831	0.89	7/20
SCHEMBL22682	0.78	7/20
SCHEMBL22683	0.78	7/20

Clinical trials — most relevant to TLK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK	PHASE3	COMPLETED
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer	PHASE2	RECRUITING
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Gene Therapy for Netherton Syndrome	PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Immune Cell Response to Stimuli	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TLK2 binder may also engage these)

Protein	Name	Similarity
Q90ZY6	—	0.999	Q90ZY6 →
O55047	—	0.995	O55047 →
Q08CW1	—	0.994	Q08CW1 →
Q1ECX4	—	0.990	Q1ECX4 →
TLK1	Serine/threonine-protein kinase tousled-like 1	0.990	landscape →
Q8C0V0	—	0.989	Q8C0V0 →
Q8BWW9	—	0.974	Q8BWW9 →
KIF23	Kinesin-like protein KIF23	0.974	landscape →
Q8WXI2	—	0.973	Q8WXI2 →
O60890	—	0.971	O60890 →
Q8BIE6	—	0.971	Q8BIE6 →
Q922G2	—	0.971	Q922G2 →
Q60611	—	0.971	Q60611 →
Q9NZI7	—	0.971	Q9NZI7 →
Q8K1Y2	—	0.971	Q8K1Y2 →
F1LTE0	—	0.971	F1LTE0 →
Q7YQL5	—	0.971	Q7YQL5 →
Q9Z1T4	—	0.971	Q9Z1T4 →
Q7YQL6	—	0.971	Q7YQL6 →
Q9UPW8	—	0.971	Q9UPW8 →
PRKD1	Serine/threonine-protein kinase D1	0.970	landscape →
CBL	E3 ubiquitin-protein ligase CBL	0.970	landscape →
Q8TAV0	—	0.970	Q8TAV0 →
Q5HYJ3	—	0.970	Q5HYJ3 →
Q6P9S0	—	0.969	Q6P9S0 →
O88574	—	0.969	O88574 →
Q9UPW6	—	0.969	Q9UPW6 →
PKN2	Serine/threonine-protein kinase N2	0.969	landscape →
BCR	Breakpoint cluster region protein	0.969	landscape →
Q9ERG2	—	0.969	Q9ERG2 →